A quarter-acre of shallow ponds, harvested every 15–18 days, can out-earn an acre of most row crops — which is the entire case for calling spirulina “green gold.” It is also, right now, an Axiom-4 astronaut’s microgravity experiment, a malnutrition supplement with a real efficacy dispute attached, an unproven biofuel feedstock, and the organism a Kerala carbon-capture startup is using to scrub CO₂ out of building air. China still grows most of the world’s supply; South Korea, it turns out, mostly buys it in.
Green Gold: What Spirulina Actually Is, and Isn't, Good For
What spirulina actually is. Not a plant, not an algae in the seaweed sense — Arthrospira platensis (commonly called spirulina) is a photosynthetic cyanobacterium that grows as a blue-green filament in shallow, warm, alkaline water. It's harvested by filtering it out of the pond, not by cutting or digging anything, which is most of why its land and water footprint per kilogram of protein is so much smaller than any land crop or livestock system.
Spirulina cultivation doesn't need farmland in the conventional sense — it needs shallow, agitated ponds or tanks (open raceway ponds are the standard low-cost design), warm temperatures, sunlight, and an alkaline nutrient mix. A batch reaches harvestable density in roughly 15–18 days, against a cereal crop's 90–120-day cycle, so a single pond turns over multiple harvests a season. Commercial setup guides circulating in India put a one-acre open-pond operation at roughly ₹2 lakh in initial investment, with dried spirulina powder selling around ₹1,000/kg and monthly revenue estimates in the ₹60,000–₹1 lakh range once the system is running — figures from industry how-to guides and trade press, not an audited farm-income survey, so treat them as commercial claims rather than verified averages. India's small and marginal farmers are eligible for up to 50% subsidy (capped around ₹5 lakh) on pond construction, with separate MSME support for drying, grinding and packaging equipment for anyone moving into processing.
The scale argument is the whole pitch: a quarter-acre to one-acre pond, requiring far less water than an equivalent area of paddy or sugarcane, can be run by a household without heavy machinery or land consolidation. One of the more visible proof points is a Karnataka grower whose backyard spirulina operation grew into supply for roughly 1.5 lakh malnourished children across the state's anganwadi supplement programme — started from exactly the small-acreage model this section describes, not a corporate plantation.
Spirulina's applications span a wide range of technical readiness, and conflating them overstates the case for any one of them.
| Application | Status | What the evidence actually shows |
|---|---|---|
| Food / nutraceutical | Commercial, mainstream | Protein-, vitamin- and mineral-dense; the largest existing market (dietary supplements, functional foods) |
| Malnutrition supplementation | Deployed by state governments, contested | Karnataka and Haryana anganwadi pilots reported reductions in child malnutrition (one study cited 46-67% reduction over six months); but spirulina is not certified as a drug under the Drugs & Cosmetics Act or as a food under FSSAI, and a National Institute of Nutrition trial was reportedly abandoned after beta-carotene (a Vitamin A precursor) levels dropped 40% in children given spirulina — a genuine open dispute, not a settled win |
| Industrial (phycocyanin, cosmetics, dyes) | Commercial, growing | The blue pigment phycocyanin is FDA/EU-approved as a natural food colourant and is a fast-growing input to K-beauty cosmetic formulations |
| Biofuel feedstock | Lab / early research, not commercial | Spirulina biomass has been fermented to ethanol at reported yields of roughly 16% (g ethanol per g biomass) after acid pre-treatment, and its oil has been converted to biodiesel via transesterification in published studies — both real results, both still lab-scale, with no commercial spirulina-to-fuel plant identified in India |
Malnutrition-supplementation figures per Haryana and Karnataka state programme reporting (ICDS/anganwadi pilots) and contemporaneous coverage of the National Institute of Nutrition trial's beta-carotene finding; treat both the efficacy claims and the counter-finding as reported, not independently re-verified here. Biofuel yield figures per published lab studies on spirulina saccharification/fermentation and transesterification, not commercial production data.
| Application | Status | What the evidence actually shows |
|---|---|---|
| Animal feed & aquaculture | Commercial, scaling | Spirulina meal (>60% protein by dry weight) improves feed efficiency, egg-yolk pigmentation and disease resistance in poultry and fish; India's largest producer, EID Parry (Tamil Nadu), is reported cultivating over 8,000 tonnes/year for this and other markets — a national, company-wide figure spanning facilities outside Tamil Nadu, not directly comparable to the ~1,500 t/yr Tamil Nadu-wide estimate cited in Section 5's table, which covers state-level production only |
| Wastewater treatment | Research to pilot scale | Spirulina cultured directly in nutrient-rich effluent (canteen, dairy, aquaculture, saline wastewater) has removed 70-92% of nitrogen and phosphorus in published studies, turning treatment cost into harvestable biomass — a genuine circular-economy pitch, but studies flag that scaling to industrial wastewater volumes cost-effectively remains unresolved |
| Natural blue colourant / textile dye | Commercial (food/cosmetics); early-stage (textiles) | Phycocyanin is sold commercially as a natural blue food colourant — DIC Corporation's "LINABLUE," extracted using only water, is one branded example — and separate published research has dyed fabric directly with spirulina powder, though textile-scale dyeing remains a design-studio/research activity, not an established industry |
| Bioplastic / packaging | Lab-stage | University of Washington researchers produced spirulina-based bioplastic that degrades in 3-4 weeks (comparable to a composting banana peel) and is roughly ten times stronger than earlier spirulina bioplastics — promising, but researchers themselves note it remains water-sensitive and brittle, with no commercial packaging product identified |
| Antiviral / immune adjunct | Clinical-trial stage | A 2024 systematic review found spirulina associated with higher CD4 counts and lower viral load in HIV/HCV patients; separate randomized controlled trials in hospitalised COVID-19 patients reported faster recovery and reduced inflammatory markers with high-dose spirulina — real peer-reviewed trial results, but on the researchers' own account, sample sizes are small and larger controlled trials are still needed before any clinical recommendation |
Animal-feed figures per market-research aggregators (Fortune Business Insights, Future Market Insights) and industry coverage of EID Parry/Parry Nutraceuticals' Tamil Nadu operations; the EID Parry tonnage is a national, company-wide figure, while the Tamil Nadu-wide tonnage cited elsewhere in this piece is state-specific — the two describe different scopes rather than conflicting on the same measurement. Wastewater-treatment removal rates per multiple peer-reviewed studies (MDPI, ScienceDirect, Springer Current Microbiology) using different effluent types — rates are not directly comparable across studies. Phycocyanin/LINABLUE per DIC Corporation's own product material; textile-dyeing research per a published De Gruyter study. Bioplastic findings per University of Washington research as covered by the World Economic Forum and EcoWatch. Antiviral/immune findings per a 2024 ScienceDirect systematic review and RCTs published in Frontiers in Immunology and other peer-reviewed journals; this piece has not evaluated study quality or sample sizes independently beyond what the source coverage itself notes.
The Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment and Employment) Policy on 24 August 2024, aimed at building India's biomanufacturing base through roughly 16 planned hubs, each carrying large-scale fermenters (500–1,000 litres) for fermentation-based medicines, biofuels, bioproteins and carbon-capture technologies. Microalgae and cyanobacteria — the taxonomic group spirulina belongs to — sit explicitly inside that framework.
The most concrete, dated result so far: under the ISRO–DBT partnership (with ICGEB, New Delhi), Indian astronaut Group Captain Shubhanshu Shukla studied an Indian isolate of spirulina and a fast-growing Synechococcus strain aboard the International Space Station as part of the Axiom-4 mission, comparing growth on nitrate versus urea as nitrogen sources under microgravity. The stated aim is twofold: test spirulina as a "superfood" for long-duration space missions (protein and vitamin density matter more, not less, off-planet), and study cyanobacteria's ability to recycle both carbon and nitrogen — a life-support angle relevant to India's own Gaganyaan human-spaceflight programme.
Carbelim, a Kerala-registered, IIT Madras-incubated climate-tech startup founded by Dr Karthika Gopi (with co-founders Gopakumar Gopalan and Rahul Babu Achakkottil), builds algae-powered systems — branded as a "Carbon Bio-Façade" — that continuously absorb CO₂ and volatile organic compounds from indoor and building air, using photobioreactors housing living Spirulina platensis cultures under LED light, producing oxygen and biomass as by-products. The underlying physics is genuinely favourable: published research on microalgae-based air remediation reports CO₂ capture rates 10–50 times faster than equivalent terrestrial plants for the same footprint, which is the whole case for using a photobioreactor instead of a houseplant wall. Carbelim raised a pre-seed round from Campus Fund in 2025 and is one of a small but growing set of India-based ventures pitching microalgae air-purification as a green-building feature rather than a lab curiosity.
China dominates global spirulina cultivation specifically — estimates range from roughly 45% (China's own Ministry of Agriculture figure, 2025) to 55–65% of world production by volume, concentrated in the warm, sun-rich provinces of Yunnan, Inner Mongolia and Shandong, with individual Chinese producers (CHINA C.B.N, F.K. DNARMSA Spirulina) each running 1,200–1,600 tonnes/year. China also accounts for roughly 40% of global spirulina powder exports. On spirulina specifically, South Korea shows up mainly on the import side — buyers including Biwell Inc, Dong Sung Bio Pharm and Mastercon Line source it from abroad rather than growing it domestically at scale.
Broaden the lens to microalgae generally, though, and Korea has real activity: Phycoil Biotech Korea (Gangnam-gu, founded on a proprietary cultivation platform developed from 2009, commercialising since 2015) is described in its own materials as the only company in Korea running commercial-scale microalgal production — more than 90 strains, though its flagship product is DHA oil for nutraceutical and pharmaceutical use, not spirulina. On the fuel side, Korean trade press has reported a signed deal between cargo carrier Air Incheon and an algae-based sustainable aviation fuel developer to trial SAF production, and S-Oil sits inside the four-refiner consortium (with SK Innovation, GS Caltex and HD Hyundai Oilbank) building a ₩1 trillion joint SAF plant — though that plant's actual feedstock focus, per the reporting available, is waste fats, oils and municipal solid waste, with algae mentioned only as one of several feedstocks the industry discusses generally, not a confirmed S-Oil-specific program. A separately circulated claim that Kumho Petrochemical built a microalgae-to-bioethanol plant at Yeosu did not check out: Kumho's real, verified Yeosu project is a CO₂ capture (CCUS) facility supplying industrial and food-grade uses, unconnected to algae cultivation in the sourcing found.
On the research side, spirulina cultivation has actually been trialled inside Korea: a published study grew Spirulina maxima in open raceway ponds at Ansan, on Korea's Yellow Sea coast, across a full annual cycle, reporting stable average biomass concentration of roughly 0.99 g/L and concluding the temperate, four-season Korean climate supports viable industrial-scale production — a genuine domestic cultivation data point, though a published research trial, not evidence of an operating commercial spirulina farm.
Net read: Korea is not a spirulina grower, but it is not merely a passive buyer of microalgae either — it has one genuine commercial-scale microalgae cultivator (Phycoil, DHA-focused) and early-stage refiner interest in algae-linked SAF, layered under a much larger, waste-oil-based national SAF push.
| Country / region | Role | Scale indicator (units vary by row: %, t/yr, $) |
|---|---|---|
| China | Dominant grower & exporter | ~45-65% of global production (estimates vary by source); ~40% of global powder exports; individual producers at 1,200-1,600 t/yr |
| India | Grower, smaller scale, export-recovering | Tamil Nadu ~1,500 t/yr (India's leading state); national spirulina export value $6.69M in 2024, export volume ~4x since 2020 |
| South Korea | Spirulina importer; microalgae grower on a separate strain | No spirulina cultivation identified at scale; imports for cosmetic/pharma-grade processing; Phycoil Biotech Korea runs commercial-scale microalgae cultivation domestically, but for DHA, not spirulina |
| Global market | — | ~USD 848M (2024) growing toward ~USD 1.3B by 2030 on most estimates; production volume estimated >20,000 t in 2024 |
China production-share estimates vary materially by source (45% per China's Ministry of Agriculture 2025 figure vs 55-65% per other industry trackers) — both are reported here rather than reconciled to one number. India export and Tamil Nadu production figures per trade-data aggregators and industry coverage, not a government export register cross-check. Global market-size figures per multiple market-research firms whose methodologies were not independently verified.
About this article: Researched, written and edited by Umashankar Triplicane Dwarakanathan, with AI research assistance; every figure is meant to trace to the primary source cited. See the Editorial Policy for how sourcing, AI use and corrections work.
.jpg){kind=link}